State of the art and challenges in sequence based T-cell epitope prediction

Immunome Research

Volumn 6, Issue SUPPL. 2, 2010, Pages

  Lundegaard, Claus ^a   Hoof, Ilka ^b   Lund, Ole ^a   Nielsen, Morten ^a  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR; VACCINE;

ANTIGEN BINDING; ANTIGEN PRESENTATION; ARTIFICIAL NEURAL NETWORK; BIOINFORMATICS; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; HUMAN; IMMUNE SYSTEM; IMMUNOINFORMATICS; INFECTION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PREDICTION; REVIEW; SUPPORT VECTOR MACHINE;

EID: 78149352601     PISSN: None     EISSN: 17457580     Source Type: Journal    
DOI: 10.1186/1745-7580-6-S2-S3     Document Type: Review

References (129)

1. Zoonotic viral diseases and the frontier of early diagnosis, control and prevention. JL Heeney, J Intern Med 2006 260 399 408 10.1111/j.1365-2796.2006. 01711.x 17040245
2. The emergence of rabbit haemorrhagic disease virus: will a non-pathogenic strain protect the UK? PJ White RA Norman RC Trout EA Gould PJ Hudson, Philos Trans R Soc Lond B Biol Sci 2001 356 1087 1095 10.1098/rstb.2001.0897 11516386
3. Coronaviruses post-SARS: update on replication and pathogenesis. S Perlman J Netland, Nat Rev Microbiol 2009 7 439 450 10.1038/nrmicro2147 19430490
4. Pathogenicity of highly pathogenic avian influenza virus in mammals. E de Wit Y Kawaoka MD de Jong RAM Fouchier, Vaccine 2008 26 Suppl 4 54 D58 10.1016/j.vaccine.2008.07.072 19230161
5. Swine-origin influenza virus H1N1, seasonal influenza virus, and critical illness in children. P Lister F Reynolds R Parslow A Chan M Cooper A Plunkett S Riphagen M Peters, Lancet 2009 374 605 607 10.1016/S0140-6736(09)61512-9 19700000
6. Modelling the progression of pandemic influenza A (H1N1) in Vietnam and the opportunities for reassortment with other influenza viruses. MF Boni BH Manh PQ Thai J Farrar TT Hien NT Hien NV Kinh P Horby, BMC Med 2009 7 43 10.1186/1741-7015-7-43 19728864
7. Pathogen recognition and innate immunity. S Akira S Uematsu O Takeuchi, Cell 2006 124 783 801 10.1016/j.cell.2006.02.015 16497588
8. New technologies for making vaccines. RW Ellis, Vaccine 1999 17 1596 1604 10.1016/S0264-410X(98)00416-2 10194811
9. Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity. CL Hutchings SC Gilbert AV Hill AC Moore, J Immunol 2005 175 599 606 15972697
10. C Janeway, Immunobiology : the immune system in health and disease New York: Garland Science 2005
11. Antigen Presentation and the Ubiquitin-Proteasome System in Host-Pathogen Interactions. J Loureiroa HL Ploegha, Advances in Immunology 2006 92 225 305 full-text 17145306
12. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. KL Rock C Gramm L Rothstein K Clark R Stein L Dick D Hwang AL Goldberg, Cell 1994 78 761 771 10.1016/S0092-8674(94)90462-6 8087844
13. Assembly and function of the two ABC transporter proteins encoded in the human major histocompatibility complex. A Kelly SH Powis LA Kerr I Mockridge T Elliott J Bastin B Uchanska-Ziegler A Ziegler J Trowsdale A Townsend, 1992
14. TAP-independent antigen presentation on MHC class I molecules: Lessons from Epstein - Barr virus. G Lautscham A Rickinson N Blake, Microbes and Infection 2003 5 291 299 10.1016/S1286-4579(03)00031-5 12706442
15. MHC class I antigen presentation: learning from viral evasion strategies. TH Hansen M Bouvier, Nat Rev Immunol 2009 9 503 513 10.1038/nri2575 19498380
16. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. B Seliger U Ritz R Abele M Bock R Tampé G Sutter I Drexler C Huber S Ferrone, Cancer Res 2001 61 8647 8650 11751378
17. TAP-Independent MHC Class I Presentation. MV Larsen M Nielsen A Weinzierl O Lund, Current Immunology Reviews 2006 2 233 245 10.2174/157339506778018550
18. Two new proteases in the MHC class I processing pathway. L Stoltze M Schirle G Schwarz C Schroter MW Thompson LB Hersh H Kalbacher S Stevanovic HG Rammensee H Schild, Nat. Immunol 2000 1 413 418 10.1038/80852 11062501
19. PRED(TAP): a system for prediction of peptide binding to the human transporter associated with antigen processing. GL Zhang N Petrovsky CK Kwoh JT August V Brusic, Immunome Res 2006 2 3 10.1186/1745-7580-2-3 16719926
20. Analysis of interactions in a tapasin/class I complex provides a mechanism for peptide selection. M Chen M Bouvier, EMBO J 2007 26 1681 1690 10.1038/sj.emboj.7601624 17332746
21. Retention of empty MHC class I molecules by tapasin is essential to reconstitute antigen presentation in invertebrate cells. GJ Schoenhals RM Krishna AG Grandea, EMBO J 1999 18 743 others 10.1093/emboj/18.3.743 9927434
22. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. JW Yewdell JR Bennink, Annu Rev Immunol 1999 17 51 88 10.1146/annurev.immunol.17.1.51 10358753
23. A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus. M Moutaftsi B Peters V Pasquetto DC Tscharke J Sidney HH Bui H Grey A Sette, Nat Biotechnol 2006 24 817 819 10.1038/nbt1215 16767078
24. Have we cut ourselves too short in mapping CTL epitopes? SR Burrows J Rossjohn J McCluskey, Trends Immunol 2006 27 11 16 10.1016/j.it.2005.11.001 16297661
25. SYFPEITHI: database for MHC ligands and peptide motifs. H Rammensee J Bachmann NP Emmerich OA Bachor S Stevanovic, Immunogenetics 1999 50 213 219 10.1007/s002510050595 10602881
26. Cellular peptide composition governed by major histocompatibility complex class I molecules. K Falk O Rotzschke HG Rammensee, Nature 1990 348 248 251 10.1038/348248a0 2234092
27. Two distinct HLA-A*0101-specific submotifs illustrate alternative peptide binding modes. A Kondo J Sidney S Southwood MF del Guercio E Appella H Sakamoto HM Grey E Celis RW Chesnut RT Kubo A Sette, Immunogenetics 1997 45 249 258 10.1007/s002510050200 9002445
28. Definition of specific peptide motifs for four major HLA-A alleles. RT Kubo A Sette HM Grey E Appella K Sakaguchi NZ Zhu D Arnott N Sherman J Shabanowitz H Michel, J Immunol 1994 152 3913 3924 8144960
29. Expression and deletion analysis of the Trypanosoma brucei rhodesiense cysteine protease in Escherichia coli. EG Pamer CE Davis M So, Infect Immun 1991 59 1074 1078 1997411
30. Exact prediction of a natural T cell epitope. O Rotzschke K Falk S Stevanovic G Jung P Walden HG Rammensee, Eur J Immunol 1991 21 2891 2894 10.1002/eji.1830211136 1718764
31. Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. A Sette S Buus E Appella JA Smith R Chesnut C Miles SM Colon HM Grey, Proc Natl Acad Sci U S A 1989 86 3296 3300 10.1073/pnas.86.9.3296 2717617
32. Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences. GE Meister CG Roberts JA Berzofsky AS De Groot, Vaccine 1995 13 581 591 10.1016/0264-410X(94)00014-E 7483779
33. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. KC Parker MA Bednarek JE Coligan, J Immunol 1994 152 163 175 8254189
34. Peptide binding specificity of major histocompatibility complex class I resolved into an array of apparently independent subspecificities: quantitation by peptide libraries and improved prediction of binding. A Stryhn LO Pedersen T Romme CB Holm A Holm S Buus, Eur J Immunol 1996 26 1911 1918 10.1002/eji.1830260836 8765039
35. Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix. JR Schafer BM Jesdale JA George NM Kouttab AS De Groot, Vaccine 1998 16 1880 1884 10.1016/S0264-410X(98)00173-X 9795396
36. HG Rammensee J Bachmann S Stevanovic, MHC ligands and Peptide Motifs New York: Chapman & Hall 1997
37. Prediction of MHC class I binding peptides using profile motifs. PA Reche JP Glutting EL Reinherz, Hum Immunol 2002 63 701 709 10.1016/S0198-8859(02) 00432-9 12175724
38. Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach. M Nielsen C Lundegaard P Worning CS Hvid K Lamberth S Buus S Brunak O Lund, Bioinformatics 2004 20 1388 1397 10.1093/bioinformatics/ bth100 14962912
39. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. B Peters A Sette, BMC Bioinformatics 2005 6 132 10.1186/1471-2105-6-132 15927070
40. Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. HH Bui J Sidney B Peters M Sathiamurthy A Sinichi KA Purton BR Mothe FV Chisari DI Watkins A Sette, Immunogenetics 2005 57 304 314 10.1007/s00251-005-0798-y 15868141
41. Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research. HH Lin S Ray S Tongchusak EL Reinherz V Brusic, BMC Immunol 2008 9 8 10.1186/1471-2172-9-8 18366636
42. A community resource benchmarking predictions of peptide binding to MHC-I molecules. B Peters HH Bui S Frankild M Nielson C Lundegaard E Kostem D Basch K Lamberth M Harndahl W Fleri SS Wilson J Sidney O Lund S Buus A Sette, PLoS Comput Biol 2006 2 65 10.1371/journal.pcbi.0020065 16789818
43. Prediction of binding to MHC class I molecules. HP Adams JA Koziol, J Immunol Methods 1995 185 181 190 10.1016/0022-1759(95)00111-M 7561128
44. Prediction of MHC binding peptides using artificial neural networks. V Brusic G Rudy LC Harrison, Complex systems: mechanism of adaptation Amsterdam: IOS Press, Stonier RJ, Yu XS, 1994 253 260
45. Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. S Buus SL Lauemoller P Worning C Kesmir T Frimurer S Corbet A Fomsgaard J Hilden A Holm S Brunak, Tissue Antigens 2003 62 378 384 10.1034/j.1399-0039.2003.00112.x 14617044
46. Two complementary methods for predicting peptides binding major histocompatibility complex molecules. K Gulukota J Sidney A Sette C DeLisi, J Mol Biol 1997 267 1258 1267 10.1006/jmbi.1997.0937 9150410
47. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. M Nielsen C Lundegaard P Worning SL Lauemøller K Lamberth S Buus S Brunak O Lund, Protein Sci 2003 12 1007 1017 10.1110/ps.0239403 12717023
48. SVMHC: a server for prediction of MHC-binding peptides. P Dönnes O Kohlbacher, Nucleic Acids Res 2006 34 194 W197 10.1093/nar/gkl284 16844990
49. The immune epitope database 2.0. R Vita L Zarebski JA Greenbaum H Emami I Hoof N Salimi R Damle A Sette B Peters, Nucleic Acids Res 2010 38 854 D862 10.1093/nar/gkp1004 19906713
50. A roadmap for the immunomics of category A-C pathogens. A Sette W Fleri B Peters M Sathiamurthy HH Bui S Wilson, Immunity 2005 22 155 161 10.1016/j.immuni.2005.01.009 15773067
51. Major histocompatibility complex class I binding predictions as a tool in epitope discovery. C Lundegaard O Lund S Buus M Nielsen, Immunology 2010 130 309 318 10.1111/j.1365-2567.2010.03300.x 20518827
52. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. C Lundegaard K Lamberth M Harndahl S Buus O Lund M Nielsen, Nucleic Acids Res 2008 36 509 W512 10.1093/nar/gkn202 18463140
53. Modeling the adaptive immune system: predictions and simulations. C Lundegaard O Lund C Kesmir S Brunak M Nielsen, Bioinformatics 2007 23 3265 3275 10.1093/bioinformatics/btm471 18045832
54. Towards in silico design of epitope-based vaccines. NC Toussaint O Kohlbacher, Expert Opin. Drug Discov 2009 4697
55. Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. C Lundegaard O Lund M Nielsen, Bioinformatics 2008 24 1397 1398 10.1093/bioinformatics/btn128 18413329
56. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. P Wang J Sidney C Dow B Mothé A Sette B Peters, PLoS Comput Biol 2008 4 1000048 10.1371/journal.pcbi.1000048 18389056
57. Several HLA alleles share overlapping peptide specificities. J Sidney MF del Guercio S Southwood VH Engelhard E Appella HG Rammensee K Falk O Rötzschke M Takiguchi RT Kubo, J Immunol 1995 154 247 259 7527812
58. Definition of supertypes for HLA molecules using clustering of specificity matrices. O Lund M Nielsen C Kesmir AG Petersen C Lundegaard P Worning C Sylvester-Hvid K Lamberth G Røder S Justesen S Buus S Brunak, Immunogenetics 2004 55 797 810 10.1007/s00251-004-0647-4 14963618
59. Identifiying human MHC supertypes using bioinformatic methods. IA Doytchinova P Guan DR Flower, J Immunol 2004 172 4314 4323 15034046
60. Definition of MHC supertypes through clustering of MHC peptide binding repertoires. PA Reche EL Reinherz, Artificial Immune Systems, Proceedings Berlin: Springer Verlag 2004 189 196 full-text
61. Definition of MHC supertypes through clustering of MHC peptide-binding repertoires. PA Reche EL Reinherz, Methods Mol Biol 2007 409 163 173 full-text 18449999
62. Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. J Sidney HM Grey S Southwood E Celis PA Wentworth MF del Guercio RT Kubo RW Chesnut A Sette, Hum Immunol 1996 45 79 93 10.1016/0198-8859(95)00173-5 8882405
63. HLA class I supertypes: a revised and updated classification. J Sidney B Peters N Frahm C Brander A Sette, BMC Immunol 2008 9 1 10.1186/1471-2172-9-1 18211710
64. Receptor-ligand interactions measured by an improved spun column chromatography technique. A high efficiency and high throughput size separation method. S Buus A Stryhn K Winther N Kirkby LO Pedersen, Biochim Biophys Acta 1995 1243 453 460 7537104
65. Peptide binding to HLA class I molecules: homogenous, high-throughput screening, and affinity assays. M Harndahl S Justesen K Lamberth G Røder M Nielsen S Buus, J Biomol Screen 2009 14 173 180 10.1177/1087057108329453 19196700
66. Measurement of MHC/peptide interactions by gel filtration. J Sidney S Southwood C Oseroff MF del Guercio A Sette HM Grey, Curr Protoc Immunol 2001 Chapter 18:Unit 18.3 18432745
67. Establishment of a quantitative ELISA capable of determining peptide-MHC class I interaction. C Sylvester-Hvid N Kristensen T Blicher H Ferre SL Lauemoller XA Wolf K Lamberth MH Nissen LO Pedersen S Buus, Tissue Antigens 2002 59 251 258 10.1034/j.1399-0039.2002.590402.x 12135423
68. Immune epitope database analysis resource (IEDB-AR). Q Zhang P Wang Y Kim P Haste-Andersen J Beaver PE Bourne HH Bui S Buus S Frankild J Greenbaum O Lund C Lundegaard M Nielsen J Ponomarenko A Sette Z Zhu B Peters, Nucleic Acids Res 2008 36 513 W518 10.1093/nar/gkn254 18515843
69. MULTIPRED: a computational system for prediction of promiscuous HLA binding peptides. GL Zhang AM Khan KN Srinivasan JT August V Brusic, Nucleic Acids Res 2005 33 172 W179 10.1093/nar/gki452 15980449
70. Efficient peptide-MHC-I binding prediction for alleles with few known binders. L Jacob JP Vert, Bioinformatics 2008 24 358 366 10.1093/bioinformatics/ btm611 18083718
71. Learning MHC I - peptide binding. N Jojic M Reyes-Gomez D Heckerman C Kadie O Schueler-Furman, Bioinformatics 2006 22 227 e235 10.1093/bioinformatics/ btl255 16873476
72. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. M Nielsen C Lundegaard T Blicher K Lamberth M Harndahl S Justesen G Røder B Peters A Sette O Lund S Buus, PLoS ONE 2007 2 796 10.1371/journal.pone.0000796 17726526
73. NetMHCpan, a method for MHC class I binding prediction beyond humans. I Hoof B Peters J Sidney LE Pedersen A Sette O Lund S Buus M Nielsen, Immunogenetics 2009 61 1 13 10.1007/s00251-008-0341-z 19002680
74. Pan-specific MHC class I predictors: a benchmark of HLA class I pan-specific prediction methods. H Zhang C Lundegaard M Nielsen, Bioinformatics 2009 25 83 89 10.1093/bioinformatics/btn579 18996943
75. The proteasome and MHC class I antigen processing. PM Kloetzel, Biochim Biophys Acta 2004 1695 225 233 10.1016/j.bbamcr.2004.10.004 15571818
76. Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII. PM Kloetzel, Nat Immunol 2004 5 661 669 10.1038/ni1090 15224091
77. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. M Nielsen C Lundegaard O Lund C Kemir, Immunogenetics 2005 57 33 41 10.1007/s00251-005- 0781-7 15744535
78. A theoretical approach towards the identification of cleavage-determining amino acid motifs of the 20 S proteasome. HG Holzhutter C Frommel PM Kloetzel, J. Mol. Biol. 1999 286 1251 1265 10.1006/jmbi.1998.2530 10047495
79. A kinetic model of vertebrate 20S proteasome accounting for the generation of major proteolytic fragments from oligomeric peptide substrates. HG Holzhutter PM Kloetzel, Biophys J 2000 79 1196 1205 10.1016/S0006-3495(00) 76374-0 10968984
80. An Algorithm for the Prediction of Proteasomal Cleavages. C Kuttler AK Nussbaum TP Dick HG Rammensee H Schild KP Hadeler, J. Mol. Biol. 2000 298 417 429 10.1006/jmbi.2000.3683 10772860
81. PAProC: a prediction algorithm for proteasomal cleavages available on the WWW. AK Nussbaum C Kuttler KP Hadeler HG Rammensee H Schild, Immunogenetics 2001 53 87 94 10.1007/s002510100300 11345595
82. Quantitative analysis of prion-protein degradation by constitutive and immuno-20S proteasomes indicates differences correlated with disease susceptibility. S Tenzer L Stoltze B Schonfisch J Dengjel M Muller S Stevanovic HG Rammensee H Schild, J Immunol 2004 172 1083 1091 14707082
83. Prediction of proteasome cleavage motifs by neural networks. C Kesmir AK Nussbaum H Schild V Detours S Brunak, Protein Eng 2002 15 287 296 10.1093/protein/15.4.287 11983929
84. Predicting proteasomal cleavage sites: a comparison of available methods. P Saxov S Buus S Brunak C Kesmir, Int. Immunol 2003 15 781 787 10.1093/intimm/dxg084 12807816
85. Pcleavage: an SVM based method for prediction of constitutive proteasome and immunoproteasome cleavage sites in antigenic sequences. M Bhasin GPS Raghava, Nucleic Acids Research 2005 33 202 W207 10.1093/nar/gki587 15988831
86. Computational prediction of the specificities of proteasome interaction with antigen protein. T Liu W Liu Z Song C Jiao M Zhu X Wang, Cell Mol Immunol 2009 6 135 142 10.1038/cmi.2009.19 19403064
87. The meaning and use of the area under a receiver operating characteristic (ROC) curve. JA Hanley BJ McNeil, Radiology 1982 143 29 36 7063747
88. Precise score for the prediction of peptides cleaved by the proteasome. I Ginodi T Vider-Shalit L Tsaban Y Louzoun, Bioinformatics 2008 24 477 483 10.1093/bioinformatics/btm616 18216070
89. Relationship between peptide selectivities of human transporters associated with antigen processing and HLA class I molecules. S Daniel V Brusic S Caillat-Zucman N Petrovsky L Harrison D Riganelli F Sinigaglia F Gallazzi J Hammer PM van Endert, J Immunol 1998 161 617 624 9670935
90. Efficient MHC class I-independent amino-terminal trimming of epitope precursor peptides in the endoplasmic reticulum. D Fruci G Niedermann RH Butler PM van Endert, Immunity 2001 15 467 476 10.1016/S1074-7613(01)00203-5 11567636
91. Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors. B Peters S Bulik R Tampe PM Van Endert HG Holzhütter, J Immunol 2003 171 1741 1749 12902473
92. Prediction of MHC-peptide binding: a systematic and comprehensive overview. EM Lafuente PA Reche, Curr Pharm Des 2009 15 3209 3220 10.2174/138161209789105162 19860671
93. Quantitative modeling of peptide binding to TAP using support vector machine. CM Diez-Rivero B Chenlo P Zuluaga PA Reche, Proteins 2010 78 63 72 10.1002/prot.22535 19705485
94. Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans. TG Tan E Mui H Cong WH Witola A Montpetit SP Muench J Sidney J Alexander A Sette ME Grigg A Maewal R McLeod, Vaccine 2010 28 3977 3989 10.1016/j.vaccine.2010.03.028 20347630
95. The transporter associated with antigen processing TAP: structure and function. B Lankat-Buttgereit R Tampe, FEBS Lett 1999 464 108 112 10.1016/S0014-5793(99)01676-2 10618487
96. Differential tapasin dependence of MHC class I molecules correlates with conformational changes upon peptide dissociation: a molecular dynamics simulation study. F Sieker TP Straatsma S Springer M Zacharias, Mol Immunol 2008 45 3714 3722 10.1016/j.molimm.2008.06.009 18639935
97. The validity of predicted T-cell epitopes. C Lundegaard M Nielsen O Lund, Trends Biotechnol 2006 24 537 538 10.1016/j.tibtech.2006.10.001 17045685
98. NetCTLpan: pan-specific MHC class I pathway epitope predictions. T Stranzl MV Larsen C Lundegaard M Nielsen, Immunogenetics 2010 62 357 368 10.1007/s00251-010-0441-4 20379710
99. MAPPP: MHC class I antigenic peptide processing prediction. J Hakenberg AK Nussbaum H Schild HG Rammensee C Kuttler HG Holzhutter PM Kloetzel SH Kaufmann HJ Mollenkopf, Appl Bioinformatics 2003 2 155 158 15130801
100. An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions. MV Larsen C Lundegaard K Lamberth S Buus S Brunak O Lund M Nielsen, Eur J Immunol 2005 35 2295 2303 10.1002/eji.200425811 15997466
101. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. S Tenzer B Peters S Bulik O Schoor C Lemmel MM Schatz PM Kloetzel HG Rammensee H Schild HG Holzhutter, Cell Mol Life Sci 2005 62 1025 1037 10.1007/s00018-005-4528-2 15868101
102. EpiJen: a server for multistep T cell epitope prediction. IA Doytchinova P Guan DR Flower, BMC Bioinformatics 2006 7 131 10.1186/1471-2105-7-131 16533401
103. Integrated modeling of the major events in the MHC class I antigen processing pathway. P Donnes O Kohlbacher, Protein Sci 2005 14 2132 2140 10.1110/ps.051352405 15987883
104. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. MV Larsen C Lundegaard K Lamberth S Buus O Lund M Nielsen, BMC Bioinformatics 2007 8 424 10.1186/1471-2105-8-424 17973982
105. Broadly immunogenic HLA class I supertype-restricted elite CTL epitopes recognized in a diverse population infected with different HIV-1 subtypes. CL Perez MV Larsen R Gustafsson MM Norstrom A Atlas DF Nixon M Nielsen O Lund AC Karlsson, J Immunol 2008 180 5092 5100 18354235
106. CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening. M Wang K Lamberth M Harndahl G Røder A Stryhn MV Larsen M Nielsen C Lundegaard ST Tang MH Dziegiel J Rosenkvist AE Pedersen S Buus MH Claesson O Lund, Vaccine 2007 25 2823 2831 10.1016/j.vaccine.2006.12.038 17254671
107. Cell mediated immunity and the inflammatory system. S Cohen, Human pathology 1976 7 249 10.1016/S0046-8177(76)80036-6 773808
108. Antigen presentation by MHC class II molecules: invariant chain function, protein trafficking, and the molecular basis of diverse determinant capture. F Castellino G Zhong RN Germain, Hum Immunol 1997 54 159 169 10.1016/S0198- 8859(97)00078-5 9297534
109. MHC Class II epitope predictive algorithms. M Nielsen O Lund S Buus C Lundegaard, Immunology 2010 130 319 328 10.1111/j.1365-2567.2010.03268.x 20408898
110. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. LJ Stern JH Brown TS Jardetzky JC Gorga RG Urban JL Strominger DC Wiley, Nature 1994 368 215 221 10.1038/368215a0 8145819
111. Sequence analysis of peptides bound to MHC class II molecules. AY Rudensky P Preston-Hurlburt SC Hong A Barlow CA Janeway, Nature 1991 353 622 627 10.1038/353622a0 1656276
112. Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J Hammer E Bono F Gallazzi C Belunis Z Nagy F Sinigaglia, J Exp Med 1994 180 2353 2358 10.1084/jem.180.6.2353 7964508
113. ProPred: prediction of HLA-DR binding sites. H Singh GP Raghava, Bioinformatics 2001 17 1236 1237 10.1093/bioinformatics/17.12.1236 11751237
114. SVM based method for predicting HLA-DRB1*0401 binding peptides in an antigen sequence. M Bhasin GP Raghava, Bioinformatics 2004 20 421 423 10.1093/bioinformatics/btg424 14960470
115. Naturally processed HLA class II peptides reveal highly conserved immunogenic flanking region sequence preferences that reflect antigen processing rather than peptide-MHC interactions. AJ Godkin KJ Smith A Willis MV Tejada-Simon J Zhang T Elliott AV Hill, J Immunol 2001 166 6720 6727 11359828
116. Peptide length-based prediction of peptide-MHC class II binding. ST Chang D Ghosh DE Kirschner JJ Linderman, Bioinformatics 2006 22 2761 2767 10.1093/bioinformatics/btl479 17000752
117. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. M Nielsen C Lundegaard O Lund, BMC Bioinformatics 2007 8 238 10.1186/1471-2105-8-238 17608956
118. Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research. HH Lin GL Zhang S Tongchusak EL Reinherz V Brusic, BMC Bioinformatics 2008 9 Suppl 12 22 10.1186/1471-2105-9-S12-S22 19091022
119. NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. M Nielsen O Lund, BMC Bioinformatics 2009 10 296 10.1186/1471-2105-10-296 19765293
120. Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan. M Nielsen C Lundegaard T Blicher B Peters A Sette S Justesen S Buus O Lund, PLoS Comput Biol 2008 4 1000107 10.1371/journal.pcbi. 1000107 18604266
121. CD4+ T cell epitope discovery and rational vaccine design. DS Rosa SP Ribeiro E Cunha-Neto, Arch Immunol Ther Exp (Warsz) 2010 58 121 130 10.1007/s00005-010-0067-0 20155490
122. Th1 cell reactivity and HLA-DR binding prediction for promiscuous recognition of MPT63 (Rv1926c), a major secreted protein of Mycobacterium tuberculosis. AS Mustafa, Scand J Immunol 2009 69 213 222 10.1111/j.1365-3083. 2008.02221.x 19281533
123. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. W Fischer S Perkins J Theiler T Bhattacharya K Yusim R Funkhouser C Kuiken B Haynes NL Letvin BD Walker BH Hahn BT Korber, Nat Med 2007 13 100 106 10.1038/nm1461 17187074
124. A mathematical framework for the selection of an optimal set of peptides for epitope-based vaccines. NC Toussaint P Dönnes O Kohlbacher, PLoS Comput Biol 2008 4 1000246 10.1371/journal.pcbi.1000246 19112482
125. OptiTope - a web server for the selection of an optimal set of peptides for epitope-based vaccines. NC Toussaint O Kohlbacher, Nucleic Acids Res 2009 37 617 W622 10.1093/nar/gkp293 19420066
126. Batf3 deficiency reveals a critical role for CD8 alpha}+ dendritic cells in cytotoxic T cell immunity. K Hildner BT Edelson WE Purtha M Diamond H Matsushita M Kohyama B Calderon BU Schraml ER Unanue MS Diamond, Science 2008 322 1097 others 10.1126/science.1164206 19008445
127. The peptide-binding specificity of HLA-A*3001 demonstrates membership of the HLA-A3 supertype. K Lamberth G Røder M Harndahl M Nielsen C Lundegaard C Schafer-Nielsen O Lund S Buus, Immunogenetics 2008 60 633 643 10.1007/s00251-008-0317-z 18769915
128. Interdisciplinary Analysis of HIV-Specific CD8+ T Cell Responses against Variant Epitopes Reveals Restricted TCR Promiscuity. I Hoof CL Pérez M Buggert RK Gustafsson M Nielsen O Lund AC Karlsson, J Immunol 2010 20363973
129. MHC motif viewer. N Rapin I Hoof O Lund M Nielsen, Immunogenetics 2008 60 759 765 10.1007/s00251-008-0330-2 18766337